Yolando | $8,500,000 | (Jan 29, 2026)
Ricursive Intelligence | $300,000,000 | (Jan 28, 2026)
Nerd Apply | $3,200,000 | (Jan 28, 2026)
Marea Therapeutics
United States
- San Francisco, CA
- 20/06/2024
- Series A
- $190,000,000
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development and has the potential to become a new treatment for patients who remain at high risk of severe cardiovascular disease due to elevated remnant cholesterol and metabolic dysfunction. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology.
- Industry Biotechnology Research
- Website https://www.mareatx.com/
- LinkedIn https://www.linkedin.com/company/marea-therapeutics/
Related People
Josh LehrerFounder
United States -
Palo Alto, California
- Proven strategic leader in both large biopharma environment and in fast-paced biotech startup environments
- Track record building and leading a highly functioning development organization developing multiple programs (large and small molecules)
- Program and clinical/regulatory leadership from pre-IND through NDA approval and successful commercial launch, including negotiation of novel registrational endpoints, accelerated approval, breakthrough designation and rare disease experience.
- Leadership role in board and investor interactions, including supporting successful initial public offering, multiple highly successful financings and podium presentations at multiple finance conferences.
- As member of Senior Management Team, experience in building a biotech company from pre-IND/series A through 4+ billion market cap and NDA.
- Business development experience leading cross-functional team to evaluate in-licensing opportunities, led successful in-licensing of Phase 3 asset
- Basic science and translational experience in cardiovascular biology, active clinical practice in cardiology
Specialties: Board certified in internal medicine, cardiovascular medicine and nuclear cardiology.
Jelou AI | $10,000,000 | (Jan 28, 2026)
Concourse | $12,000,000 | (Jan 28, 2026)
Summize | $50,000,000 | (Jan 28, 2026)
FLORA(US) | $42,000,000 | (Jan 28, 2026)
Fortitude Biomedicines | $13,000,000 | (Jan 28, 2026)
Fiddler AI | $30,000,000 | (Jan 28, 2026)
Chamelio | $10,000,000 | (Jan 28, 2026)
Opendate | $14,000,000 | (Jan 28, 2026)
Memcyco | $37,000,000 | (Jan 28, 2026)
Midship | $4,150,000 | (Jan 28, 2026)